FDA Orange Book
Generic for Daypro
Daypro contains oxaprozin. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Daypro is oxaprozin. 4 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Daypro and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Daypro products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 600MG | Discontinued | None | 4 | AB |
NDA 018841, held by PFIZER INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic oxaprozin
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| DR REDDYS LABORATORIES LTD | 075855 | AB (A-rated, therapeutically equivalent) | January 31, 2001 | 600MG |
| PANGEA PHARMACEUTICALS LLC | 075845 | AB (A-rated, therapeutically equivalent) | January 31, 2001 | 600MG |
| CHARTWELL LIFE MOLECULES LLC | 075987 | AB (A-rated, therapeutically equivalent) | September 2, 2004 | 600MG |
| AMNEAL PHARMACEUTICALS CO GMBH | 208633 | AB (A-rated, therapeutically equivalent) | May 4, 2017 | 600MG |
Questions
Is there a generic for Daypro?
Yes. The generic name for Daypro is oxaprozin. 4 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Daypro?
The active ingredient in Daypro is oxaprozin, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.